When it comes to results, few people deliver like President Donald Trump. 

During my four years in the White House as special assistant to the president for legislative affairs and then deputy assistant to the president for strategic initiatives, I had a front-row seat to watch it.

But he cannot fix a problem he does not know about. Case in point? The Food and Drug Administration’s lethargy on approving treatments for children with rare, and often fatal, diseases.

Recommended Stories

Delay is a death sentence. Why rare disease families don’t trust Trump’s FDA nominee

The FDA keeps breaking its word to dying patients

Stop forcing vets abroad: Trump’s FDA is bringing a game-changing PTSD treatment home